Marie Sandström
Marie Sandström
COO, Deputy CEO, Pharmetheus AB
Verified email at
Cited by
Cited by
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments
EI Nielsen, A Viberg, E Löwdin, O Cars, MO Karlsson, M Sandström
Antimicrobial agents and chemotherapy 51 (1), 128-136, 2007
Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats
LE Friberg, A Freijs, M Sandström, MO Karlsson
Journal of Pharmacology and Experimental Therapeutics 295 (2), 734-740, 2000
Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
M Hassan, A Fasth, B Gerritsen, A Haraldsson, Z Syrůcková, ...
Bone marrow transplantation 18 (5), 843-850, 1996
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients
A Henningsson, A Sparreboom, M Sandström, A Freijs, R Larsson, ...
European Journal of Cancer 39 (8), 1105-1114, 2003
Developmental pharmacokinetics of gentamicin in preterm and term neonates
EI Nielsen, M Sandström, PH Honoré, U Ewald, LE Friberg
Clinical pharmacokinetics 48 (4), 253-263, 2009
Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients
M Sandström, H Lindman, P Nygren, M Johansson, J Bergh, MO Karlsson
Cancer chemotherapy and pharmacology 58 (2), 143-156, 2006
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
ABMH M Sandström, M O Karlsson, P Ljungman, Z Hassan, E N Jonsson, C Nilsson ...
Bone Marrow Transplantation 28 (7), 657-664, 2001
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients
M Sandstrom, H Lindman, P Nygren, E Lidbrink, J Bergh, MO Karlsson
Journal of clinical oncology 23 (3), 413-421, 2005
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.
M Sandström, A Freijs, R Larsson, P Nygren, ML Fjällskog, J Bergh, ...
Journal of clinical oncology 14 (5), 1581-1588, 1996
Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease
T Omari, P Lundborg, M Sandström, P Bondarov, M Fjellman, R Haslam, ...
The Journal of pediatrics 155 (2), 222-228, 2009
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model
LE Friberg, M Sandström, MO Karlsson
Investigational new drugs 28 (6), 744-753, 2010
Pharmacokinetic/pharmacodynamic modelling in oncological drug development
MO Karlsson, T Anehall, LE Friberg, A Henningsson, C Kloft, ...
Basic & clinical pharmacology & toxicology 96 (3), 206-211, 2005
Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo
S Hassan, S Dhar, M Sandström, D Arsenau, M Budnikova, I Lokot, ...
Cancer chemotherapy and pharmacology 55 (1), 47-54, 2005
The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic …
A Lannergård, A Viberg, O Cars, MO Karlsson, M Sandström, A Larsson
Scandinavian journal of infectious diseases 41 (9), 663-671, 2009
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function
A Viberg, A Lannergård, A Larsson, O Cars, MO Karlsson, M Sandström
British journal of clinical pharmacology 62 (3), 297-303, 2006
Determination of cefuroxime in human serum or plasma by liquid chromatography with electrospray tandem mass spectrometry
A Viberg, M Sandström, B Jansson
Rapid communications in mass spectrometry 18 (6), 707-710, 2004
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
EK Hansson, JE Wallin, H Lindman, M Sandström, MO Karlsson, ...
Cancer chemotherapy and pharmacology 65 (5), 839-848, 2010
The pharmacokinetics of epirubicin and docetaxel in combination in rats
M Sandström, LE Simonsen, A Freijs, MO Karlsson
Cancer chemotherapy and pharmacology 44 (6), 469-474, 1999
Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response
JC Earp, N Mehrotra, KE Peters, RP Fiorentino, D Griebel, SC Lee, ...
Journal of pediatric gastroenterology and nutrition 65 (3), 272-277, 2017
Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to …
M Sandström, G Davidson, V Tolia, JE Sullivan, G Långström, P Lundborg, ...
Clinical therapeutics 34 (8), 1828-1838, 2012
The system can't perform the operation now. Try again later.
Articles 1–20